Aplastic anaemia with 13q-: A benign subset of bone marrow failure responsive to immunosuppressive therapy

British Journal of Haematology

Volumn 117, Issue 3, 2002, Pages 747-750

  Ishiyama, Ken ^a   Karasawa, Masamitsu ^b   Miyawaki, Shuichi ^c   Ueda, Yasunori ^d   Noda, Masaaki ^e   Wakita, Atsushi ^f   Sawanobori, Masakazu ^g   Nagai, Hirokazu ^h   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^g JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

13q deletion; Aplastic anaemia; Benign clinical course; Immunosuppressive therapy; Innocent clones

Indexed keywords

CYCLOSPORIN A; DANAZOL; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OXYMETHOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW HYPOPLASIA; CHROMOSOME 13Q; CHROMOSOME DELETION 13; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASIA; PANCYTOPENIA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA, APLASTIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036098795     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03518.x     Document Type: Article

References (12)

1. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia
2. What is the definition of cure for aplastic anemia?
3. Abnormal cytogenetic clones in patients with aplastic anaemia: Response to immunosuppressive therapy
4. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome
5. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone
6. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome
7. Annotation: Is aplastic anaemia a preleukaemic disorder?
8. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European blood and marrow transplantation (EBMT) severe aplastic anaemia working party
9. Cytogenetic abnormalities in patients with severe aplastic anemia
10. Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy
11. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes
12. Dysmyelopoietic syndrome: Sequential clinical and cytogenetic studies